Glaxo Sees Hope for Respiratory Drugs as Earnings Beat Estimates
This article is for subscribers only.
GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, signaled the start of a turnaround in its troubled respiratory medicine business as the company reported fourth-quarter earnings that beat analyst estimates.
After struggling with slumping U.S. sales for its lung medicines, Glaxo may have turned a corner by cutting prices to gain access to the lists of drugs that payers will reimburse, Chief Executive Officer Andrew Witty said.